NCT03583762

Brief Summary

This is an experimental study of participants who had positive blood culture to compare time to appropriate antibiotic between using Microarray Assay and Mass Spectrometry to bacterial Identification.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 15, 2018

Completed
26 days until next milestone

First Posted

Study publicly available on registry

July 11, 2018

Completed
19 days until next milestone

Study Start

First participant enrolled

July 30, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2019

Completed
Last Updated

July 11, 2018

Status Verified

July 1, 2018

Enrollment Period

5 months

First QC Date

June 15, 2018

Last Update Submit

July 10, 2018

Conditions

Keywords

Microarray Assay TechniqueMass Spectrometry TechniqueTime to appropriate antibiotic

Outcome Measures

Primary Outcomes (1)

  • To compare the time to appropriate antibiotic therapy in patients with positive blood cultures between using Microarray assays versus Mass Spectrometry technique for Identification of Positive Blood Cultures

    Comparison of time that participants received appropriate antibiotic therapy between 2 study period (Mass spectrometry technique and Microarray assay group)

    4 days from positive hemoculture

Secondary Outcomes (4)

  • Mortality rate at 2 weeks

    14 days from positive hemoculture

  • Length of hospital stays

    30 days

  • Cost of antibiotic therapy

    14 days

  • Percentage of De-escalation or escalation antibiotic

    14 days

Study Arms (2)

Pre-intervention group

EXPERIMENTAL

100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique

Diagnostic Test: Mass spectrometry

Post-intervention group

EXPERIMENTAL

100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique

Diagnostic Test: Microarray assay

Interventions

Mass spectrometryDIAGNOSTIC_TEST

Molecular diagnostic test for bacterial identification from bacterial colony

Pre-intervention group
Microarray assayDIAGNOSTIC_TEST

Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment

Post-intervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 year old with positive hemoculture between June 2018 and Dec 2018
  • Internal medicine wards patients at Maharaj Nakorn Chiang Mai Hospital
  • Ability to provide informed consent

You may not qualify if:

  • Suspected contaminated positive blood culture
  • Bacteremia cause by more than two species of bacteria, as suspected from the gram staining examinations
  • Terminally ill patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maharaj Nakorn Chiang Mai Hospital, Department of Medicine, Chiang Mai University

Chiang Mai, 50200, Thailand

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Parichart Sakulkonkij, MD

    Chiang Mai University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Parichart Sakulkonkij, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 15, 2018

First Posted

July 11, 2018

Study Start

July 30, 2018

Primary Completion

December 31, 2018

Study Completion

March 31, 2019

Last Updated

July 11, 2018

Record last verified: 2018-07

Locations